Tovinontrine
Tovinontrine (IMR-687) is a highly potent and selective phosphodiesterase-9 (PDE9) inhibitor specifically for the treatment of sickle cell disease. IC50s are 8.19 nM and 9.99 nM for PDE9A1 and PDE9A2, respectively[1].
Product Specifications
CAS Number
[2062661-53-2]
Product Name Alternative
IMR-687
UNSPSC
12352005
Hazard Statement
H302, H315, H319
Target
Phosphodiesterase (PDE)
Type
Reference compound
Related Pathways
Metabolic Enzyme/Protease
Applications
Neuroscience-Neuromodulation
Field of Research
Cardiovascular Disease
Assay Protocol
https://www.medchemexpress.com/tovinontrine.html
Concentration
10mM
Purity
99.83
Solubility
DMSO : 100 mg/mL (ultrasonic)
Smiles
O=C1C2=CN=C(C3CCOCC3)N2C=C([C@@H]4CN(CC5=NC=CC=N5)C[C@H]4C)N1
Molecular Formula
C21H26N6O2
Molecular Weight
394.47
Precautions
H302, H315, H319
References & Citations
[1]James G McArthur, et al. A novel, highly potent and selective phosphodiesterase-9 inhibitor for the treatment of sickle cell disease. Haematologica. 2020 Mar;105 (3) :623-631.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Phase 2
Isoform
PDE1; PDE5; PDE9
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
133505-ML490 100 µL
SLC6A11 (GABT3, GAT3, Sodium- and Chloride-dependent GABA Transporter 3, Solute Carrier Family 6 Member 11, GAT-3) (MaxLight 490)
Ask
View Details 